In vitro effects of eslicarbazepine (S‐licarbazepine) as a potential precision therapy on SCN8A variants causing neuropsychiatric disorders

Variants in SCN8A, the NaV1.6 channel's coding gene, are characterized by a variety of symptoms, including intractable epileptic seizures, psychomotor delay, progressive cognitive decline, autistic features, ataxia or dystonia. Standard anticonvulsant treatment has a limited impact on the course of disease.

[1]  Christopher H George,et al.  Planning experiments: Updated guidance on experimental design and analysis and their reporting III , 2022, British journal of pharmacology.

[2]  Adam J Pawson,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels , 2021, British journal of pharmacology.

[3]  H. Lerche,et al.  Therapeutic Potential of Sodium Channel Blockers as a Targeted Therapy Approach in KCNA1-Associated Episodic Ataxia and a Comprehensive Review of the Literature , 2021, Frontiers in Neurology.

[4]  Ethan M. Goldberg,et al.  Rational Small Molecule Treatment for Genetic Epilepsies , 2021, Neurotherapeutics.

[5]  H. Beck,et al.  Complex effects of eslicarbazepine on inhibitory micro networks in chronic experimental epilepsy , 2021, Epilepsia.

[6]  J. Parent,et al.  Variant-specific changes in persistent or resurgent sodium current in SCN8A-related epilepsy patient-derived neurons. , 2020, Brain : a journal of neurology.

[7]  Christopher H George,et al.  ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020 , 2020, British journal of pharmacology.

[8]  Ulrich Dirnagl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research* , 2020, BMC Veterinary Research.

[9]  W. Brackenbury,et al.  Inhibitory Effect of Eslicarbazepine Acetate and S-Licarbazepine on Nav1.5 Channels , 2020, bioRxiv.

[10]  Ethan M. Goldberg,et al.  A single‐center SCN8A‐related epilepsy cohort: clinical, genetic, and physiologic characterization , 2019, Annals of clinical and translational neurology.

[11]  G. Carvill,et al.  SCN8A: When Neurons Are So Excited, They Just Can’t Hide It , 2019, Epilepsy currents.

[12]  Romain Brette,et al.  Brian 2: an intuitive and efficient neural simulator , 2019, bioRxiv.

[13]  H. Lerche,et al.  Neuronal mechanisms of mutations in SCN8A causing epilepsy or intellectual disability , 2019, Brain : a journal of neurology.

[14]  I. Scheffer,et al.  The phenotype of SCN8A developmental and epileptic encephalopathy , 2018, Neurology.

[15]  H. Beck,et al.  Effects of eslicarbazepine on slow inactivation processes of sodium channels in dentate gyrus granule cells , 2018, Epilepsia.

[16]  J. Xiong,et al.  Early-onset epileptic encephalopathy with de novo SCN8A mutation , 2018, Epilepsy Research.

[17]  I. Scheffer,et al.  Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies , 2018, Pharmacological Reviews.

[18]  Liping Wei,et al.  SCN8A mutations in Chinese patients with early onset epileptic encephalopathy and benign infantile seizures , 2017, BMC Medical Genetics.

[19]  P. Striano,et al.  Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy , 2017, Brain and Development.

[20]  C. Barba,et al.  Diagnostic Targeted Resequencing in 349 Patients with Drug‐Resistant Pediatric Epilepsies Identifies Causative Mutations in 30 Different Genes , 2017, Human mutation.

[21]  E. Ben-Menachem,et al.  Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies , 2017, Journal of Neurology.

[22]  R. Møller,et al.  Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers , 2015, Neurotherapeutics.

[23]  D. Lindhout,et al.  Remarkable Phenytoin Sensitivity in 4 Children with SCN8A-related Epilepsy: A Molecular Neuropharmacological Approach , 2015, Neurotherapeutics.

[24]  I. Vida,et al.  Carbamazepine and oxcarbazepine, but not eslicarbazepine, enhance excitatory synaptic transmission onto hippocampal CA1 pyramidal cells through an antagonist action at adenosine A1 receptors , 2015, Neuropharmacology.

[25]  P. Soares-da-Silva,et al.  Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action , 2015, Pharmacology research & perspectives.

[26]  H. Beck,et al.  Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug. , 2015, Brain : a journal of neurology.

[27]  P. Soares-da-Silva,et al.  Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide , 2015, Neuropharmacology.

[28]  R. Møller,et al.  Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers , 2015, Neurotherapeutics.

[29]  H. Beck,et al.  Impaired Action Potential Initiation in GABAergic Interneurons Causes Hyperexcitable Networks in an Epileptic Mouse Model Carrying a Human NaV1.1 Mutation , 2014, The Journal of Neuroscience.

[30]  W. Wadman,et al.  Properties of human brain sodium channel α‐subunits expressed in HEK293 cells and their modulation by carbamazepine, phenytoin and lamotrigine , 2014, British journal of pharmacology.

[31]  H. Beck,et al.  The effects of eslicarbazepine on persistent Na+ current and the role of the Na+ channel β subunits , 2013, Journal of the Neurological Sciences.

[32]  M. Meisler,et al.  Sodium channel SCN8A (Nav1.6): properties and de novo mutations in epileptic encephalopathy and intellectual disability , 2013, Front. Genet..

[33]  A. Falcão,et al.  Steady‐state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers , 2013, Epilepsia.

[34]  A. Aldenkamp,et al.  Cognitive side-effects of antiepileptic drugs in children. , 2013, Handbook of clinical neurology.

[35]  M. Bialer,et al.  Pharmacokinetics and drug interactions of eslicarbazepine acetate , 2012, Epilepsia.

[36]  K. Veeramah,et al.  De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. , 2012, American journal of human genetics.

[37]  C. Elger,et al.  Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures , 2011, Epilepsy Research.

[38]  Dr. R. L. Macdonald.  Anticonvulsant drug actions on neurons in cell culture , 2005, Journal of Neural Transmission.

[39]  S. Tate,et al.  Heterologous expression and functional analysis of rat NaV1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7–23 , 2004, Neuropharmacology.

[40]  R. Sheridan,et al.  Interaction of the Novel Anticonvulsant, BIA 2‐093, with Voltage‐Gated Sodium Channels: Comparison with Carbamazepine , 2001, Epilepsia.

[41]  R. Traub,et al.  Multiple Modes of Neuronal Population Activity Emerge after Modifying Specific Synapses in a Model of the CA3 Region of the Hippocampus , 1991, Annals of the New York Academy of Sciences.